Phase 2 N=260 Leprosy Skin Test Antigens Trial
Leprosy
Primary: Number of Participants With Reactions to the Antigen Mycobacterium (M.) Leprae Soluble Antigen (MLSA)-Lipoarabinomannan (LAM) at Doses of 0.1 Microgram — 0; 3; 1; 5…
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 3 N=94,127 Post ExpOsure Prophylaxis for LEprosy in the Comoros and Madagascar
Leprosy
Primary: Compare Effectiveness in Curbing Transmission of Leprosy of Three Different Approaches of Post Exposure Prophylaxis — 1.04; 1.42; 0.98; 0.92 number of new cases per 1000…
Phase 2 N=313 Bedaquiline Enhanced Post ExpOsure Prophylaxis for Leprosy (Phase 2)
Leprosy
Primary: Mean Difference in QTc Interval Between the Two Arms 24 Hours After Treatment Administration — 396.81; 397; 404.61; 394.06 msec
N/A N=15 γ-irradiated BCG to Train Innate Immunity
Innate Immune Response
Primary: Cytokine Production Measured by ELISA Compared to Baseline — 1.2 ratio
Phase 2 N=7 Phase II Trial of Peginterferon Alpha-2b and Thalidomide in Adults With Recurrent Gliomas
Glioma
Primary: Progression-free Survival
Phase 3 N=159 Thalidomide for the Treatment of Hormone-Dependent Prostate Cancer
Prostate Cancer
Primary: Time to Progression — 15; 9.6 months